| Title |
Induction and add-on therapy with Mitoxantrone and Interferon beta in multiple sclerosis
|
|---|---|
| Published in |
Neurological Sciences, August 2008
|
| DOI | 10.1007/s10072-008-0946-x |
| Pubmed ID | |
| Authors |
Mauro Zaffaroni, Annalisa Rizzo, Silvana Maria Baldini, Angelo Ghezzi, Giancarlo Comi |
| Abstract |
We retrospectively analyzed data from 70 multiple sclerosis (MS) patients treated with mitoxantrone (MX) before Interferon-beta (IFN-beta) because of clinically and MRI very active isolated syndrome (CIS) or relapsing-remitting MS (induction therapy) or due to breakthrough/persistently active disease in spite of IFN-beta (add-on/combination therapy), or for increased disability suggesting a secondary progression (rescue therapy). After almost 2-year follow-up, relapse rate and disability decreased very significantly in the two former groups while MX was essentially ineffective as rescue therapy. Induction therapy is a valid option for very aggressive/active CIS and MS at onset. |
Mendeley readers
The data shown below were compiled from readership statistics for 20 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 1 | 5% |
| Unknown | 19 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 4 | 20% |
| Student > Postgraduate | 3 | 15% |
| Professor | 2 | 10% |
| Professor > Associate Professor | 2 | 10% |
| Student > Master | 2 | 10% |
| Other | 4 | 20% |
| Unknown | 3 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 11 | 55% |
| Neuroscience | 3 | 15% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 5% |
| Unknown | 5 | 25% |